Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1031 studies found for:    Interferon alfa-2 OR Roferon-A (2a), Intron A (2b)[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Terminated
Has Results
Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma
Conditions: Lymphoma;   Precancerous/Nonmalignant Condition
Interventions: Biological: PEG-interferon alfa-2b;   Biological: Interferon alfa-2b;   Drug: Valproic Acid;   Drug: Zidovudine;   Genetic: Molecular Evaluation/Analysis of Malignant Clones of ATLL;   Genetic: NF-kB Inhibition
2 Completed Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Recurrent Renal Cell Cancer;   Stage III Melanoma;   Stage IV Melanoma;   Stage IV Renal Cell Cancer
Interventions: Biological: recombinant interferon alfa-2b;   Drug: amifostine/azacitidine
3 Active, not recruiting Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
Conditions: Conjunctival Intraepithelial Neoplasia;   Corneal Intraepithelial Neoplasia
Interventions: Drug: Mitomycin C;   Drug: Interferon Alfa-2b
4 Active, not recruiting Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
Conditions: Stage IA Skin Melanoma;   Stage IB Skin Melanoma;   Stage IIA Skin Melanoma;   Stage IIB Skin Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
5 Terminated Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
Conditions: Breast Cancer;   Metastatic Cancer
Interventions: Biological: PEG-interferon alfa-2a;   Drug: Capecitabine
6 Terminated
Has Results
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Decitabine;   Drug: Interferon Alfa-2b
7 Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
8 Completed Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Regional Gastrointestinal Carcinoid Tumor
Interventions: Biological: PEG-interferon alfa-2b;   Biological: bevacizumab;   Other: laboratory biomarker analysis
9 Completed Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a
Conditions: Birdshot Chorioretinopathy;   Cystoid Macular Edema;   Transient Partial Visual Loss
Interventions: Drug: interferon alpha 2a;   Drug: prednisone
10 Recruiting Pegylated Interferon Alpha-2b and Capecitabine in Unresectable/Metastatic Cutaneous Squamous Cell
Conditions: Squamous Cell Carcinoma of Skin;   Carcinoma, Squamous Cell
Interventions: Drug: Pegylated Interferon alpha-2b;   Drug: Capecitabine
11 Completed Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C
Condition: Hepatitis C
Intervention: Drug: Pegylated interferon alfa-2a
12 Active, not recruiting Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Condition: Melanoma
Interventions: Drug: Temozolomide (TMZ);   Drug: Pegylated Interferon Alpha-2b (PGI)
13 Withdrawn Study to Evaluate Sodium Stibogluconate With Interferon Alpha-2b
Conditions: Advanced Cancer;   Solid Tumors
Interventions: Drug: Sodium Stibogluconate;   Drug: Interferon Alpha-2b
14 Completed Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
Conditions: Advanced Cancer;   Solid Tumors
Interventions: Drug: Sodium Stibogluconate;   Drug: Interferon Alpha-2b
15 Terminated Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: peginterferon alfa-2b;   Drug: decitabine;   Other: laboratory biomarker analysis
16 Recruiting Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Aspirin
17 Recruiting Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
Condition: Cutaneous Melanoma
Interventions: Biological: CSF470 vaccine, BCG, Molgramostim;   Drug: interferon alpha 2b
18 Recruiting Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
Conditions: Lymphoma, T-Cell, Cutaneous;   Mycosis Fungoides
Interventions: Drug: Methotrexate;   Drug: Interferon Alfa-2b
19 Completed
Has Results
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Peginterferon alfa-2a and ribavirin;   Drug: Peginterferon alfa-2a
20 Terminated
Has Results
Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer
Condition: Cervical Cancer
Interventions: Biological: recombinant interferon alpha-2b;   Drug: isotretinoin;   Drug: paclitaxel

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years